NASDAQ$ARWR
Arrowhead Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fiscal year end results for 2023.
Arrowhead Pharmaceuticals announced its financial results for the fiscal year ended September 30, 2023. The company highlighted recent presentations of Phase 2 clinical data and the completion of toxicology studies for pulmonary candidates.
- Presented new Phase 2 clinical data from SHASTA-2, MUIR, and ARCHES-2 studies at the American Heart Association Scientific Sessions.
- Hosted a webinar featuring experts to discuss plozasiran in the context of lipid and lipoprotein disorder treatments.
- Completed chronic GLP toxicology for pulmonary candidates ARO-RAGE and ARO-MMP7 with encouraging results.
- Filed for regulatory clearance to initiate a Phase 1/2a study of ARO-DM1 for patients with type 1 myotonic dystrophy.
Headline financials
Revenue & EPS history
Arrowhead Pharmaceuticals · Revenue · Quarterly
$16.1M
Forward guidance
Arrowhead Pharmaceuticals did not provide specific financial guidance for future periods in this report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.0%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+10.8%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+39.2%
Q4 2024
Best reaction
-26.7%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.6% | +0.1% | -6.1% | |
| Q1 2026 | -0.2% | -4.8% | -7.5% | |
| Q4 2025 | +23.2% | +20.2% | +49.9% | |
| Q2 2025 | +9.4% | +12.5% | +16.1% | |
| Q1 2025 | -5.2% | +0.2% | -24.3% | |
| Q4 2024 | +39.2% | +38.5% | +3.9% | |
| Q3 2024 | -6.4% | -8.6% | -11.1% | |
| Q2 2024 | -12.5% | -9.2% | -5.2% | |
| Q1 2024 | -1.2% | +1.7% | +3.7% | |
| Q4 2023 | -26.7% | -13.8% | +5.8% | |
| Q3 2023 | -13.1% | -8.8% | -7.7% | |
| Q2 2023 | +12.5% | +15.8% | -2.9% | |
| Q1 2023 | -8.5% | -9.9% | -19.3% | |
| Q4 2022 | +1.7% | +15.0% | +27.3% | |
| Q3 2022 | +3.6% | +2.5% | -11.1% | |
| Q2 2022 | -11.5% | -3.3% | -0.7% | |
| Q1 2022 | -11.1% | -5.4% | -22.1% | |
| Q4 2021 | -0.3% | +1.3% | -1.8% | |
| Q3 2021 | -2.0% | -7.4% | +2.2% | |
| Q2 2021 | -5.4% | -5.5% | +3.2% | |
| Q1 2021 | +12.6% | +11.8% | -14.1% | |
| Q4 2020 | -12.2% | -8.4% | +24.1% | |
| Q3 2020 | -7.0% | -8.5% | -18.3% | |
| Q2 2020 | -0.3% | +5.0% | -0.5% | |
| Q1 2020 | -6.4% | -2.4% | -23.9% | |
| Q4 2019 | +37.6% | +48.4% | +31.2% | |
| Q3 2019 | -2.1% | -0.2% | +17.6% | |
| Q2 2019 | +8.0% | +0.1% | +50.2% | |
| Q1 2019 | +13.2% | +25.4% | +33.0% | |
| Q4 2018 | +11.2% | +4.8% | +9.8% | |
| Q3 2018 | +13.2% | +18.6% | +36.2% | |
| Q2 2018 | +15.8% | +27.2% | +33.5% | |
| Q1 2018 | -6.2% | -3.4% | +30.9% | |
| Q4 2017 | -3.1% | -10.5% | +43.6% | |
| Q3 2017 | +8.9% | +13.6% | +69.2% | |
| Q2 2017 | +13.5% | +6.4% | +3.8% | |
| Q1 2017 | +3.2% | +3.7% | +12.1% | |
| Q4 2016 | +0.0% | -1.6% | +62.2% | |
| Q3 2016 | -1.2% | +1.0% | +29.7% | |
| Q2 2016 | -3.1% | — | — | |
| Q1 2016 | -0.9% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | +12.1% | — | — | |
| Q2 2015 | -10.9% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -10.7% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | +2.5% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -7.2% | — | — | |
| Q3 2012 | -16.8% | — | — | |
| Q2 2012 | -4.5% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | +0.5% | — | — | |
| Q2 2011 | +0.5% | — | — | |
| Q3 2011 | -12.4% | — | — | |
| Q3 2010 | -12.4% | — | — | |
| Q4 2010 | -12.4% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q2 2010 | -8.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro